Balance Sheet
AssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Non-Current Assets (2019 - 2025)

Benitec Biopharma's Non-Current Assets history spans 5 years, with the latest figure at $355000.0 for Q4 2024.

  • For Q4 2024, Non-Current Assets fell 36.27% year-over-year to $355000.0; the TTM value through Dec 2024 reached -$66.9 million, down 1124.59%, while the annual FY2024 figure was $536000.0, 27.07% down from the prior year.
  • Non-Current Assets for Q4 2024 was $355000.0 at Benitec Biopharma, up from -$68.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $1.2 million in Q2 2022 and bottomed at -$68.3 million in Q3 2024.
  • The 5-year median for Non-Current Assets is $641000.0 (2023), against an average of -$6.5 million.
  • The largest annual shift saw Non-Current Assets soared 106.32% in 2022 before it plummeted 10760.69% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $778000.0 in 2020, then crashed by 2204.37% to -$16.4 million in 2021, then skyrocketed by 106.32% to $1.0 million in 2022, then tumbled by 46.13% to $557000.0 in 2023, then crashed by 36.27% to $355000.0 in 2024.
  • Per Business Quant, the three most recent readings for BNTC's Non-Current Assets are $355000.0 (Q4 2024), -$68.3 million (Q3 2024), and $536000.0 (Q2 2024).